

Table S1. RT-PCR primers

GENE	Sequence
SDC1-F	5'-CTGCCGCAAATTGTGGCTAC-3'
SDC1-R	5'-TGAGCCGGAGAAGTTGTCAGA-3'
CHRM3-F	5'-CACAATAACAGTACAACCTCGCC-3'
CHRM3-R	5'-GCCAGGATGCCCGTTAAGAAA-3'
HTR2C-F	5'-CTAATTGGCCTATTGGTTTGGCA-3'
HTR2C-R	5'-CCACCATCGGAGGTATTGAAAA-3'
CD22-F	5'-GCACCCTGAAACCCTCTACG-3'
CD22-R	5'-ATCAAACCTTCGAGGTGTTCTTGT-3'
CD72-F	5'-ATCTGAGGTTTGTGAAGGCTCC-3'
CD72-R	5'-AACATTCTCGTAGGTGATTTCCC-3'
CD19-F	5'-CCCAAGGGGCCTAAGTCATTG-3'
CD19-R	5'-AACAGACCCGTCTCCATTACC-3'
GAPDH-F	5'-TGCACCACCAACTGCTTAGC-3'
GAPDH-R	5'-GGCATGGACTGTGGTCATGAG-3'

Table S2. Clinicopathologic characteristics of PBL patients in our study

Variable	Total N (%)
Patients	102
Age (years)	
>60	39(38.2)
≤60	63(61.8)
Median (years)	55
Sex	
Male	68(66.7)
Female	34(33.3)
Site(s) of involvement	
Lymph involvement	24(23.5)
Gastro-intestinal tractus	20(19.6)
Oral cavity	16(15.7)
bone	12(11.8)
skin	7(6.9)
Ear, nose, throat site	6(5.9)
lung	5(4.9)
Maxillary sinus	3(2.9)
peritoneum	3(2.9)
liver	2(2.0)
adrenal gland	2(1.9)
uterus	1(1.0)
Soft tissue	1(1.0)
Immunohistochemistry	
CD38	49/55 (89.1)
CD138	54/79 (68.3)
MUM1	77/86 (89.5)
EBER	15/36
Ki67 (median)	80.0%

Table S3. Clinicopathologic characteristics of PBL patients and DLBCL patients for RNA sequencing in our study

Variable	DLBCL	PBL	<i>P</i> value
Patients	11	6	
Age (years)			>0.99
>60	5	3	
≤60	6	3	
Sex			>0.99
Male	8	5	
Female	3	1	
Primary site(s)			>0.99
Lymph node	1	1	
Extranodal sites	10	5	
Ann Arbor stage			>0.99
I or II	7	4	
III or IV	4	2	

Figure S1









Figure S2

